Your browser doesn't support javascript.
loading
Position Statement on the management of continuous subcutaneous insulin infusion (CSII): The Italian Lazio experience.
Maurizi, Anna R; Suraci, Concetta; Pitocco, Dario; Schiaffini, Riccardo; Tubili, Claudio; Morviducci, Lelio; Giordano, Renato; Manfrini, Silvia; Lauro, Davide; Frontoni, Simona; Pozzilli, Paolo; Buzzetti, Raffaella.
Afiliación
  • Maurizi AR; Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy.
  • Suraci C; Diabetes Unit, Sandro Pertini Hospital, Rome, Italy.
  • Pitocco D; Department of Systems Medicine, Catholic University School of Medicine, Rome, Italy.
  • Schiaffini R; Division of Endocrinology and Diabetes, Bambino Gesù Children's Hospital, Rome, Italy.
  • Tubili C; Diabetes Unit, San Camillo-Forlanini Hospital, Rome, Italy.
  • Morviducci L; Diabetes Unit, San Camillo-Forlanini Hospital, Rome, Italy.
  • Giordano R; Diabetes Unit, Santo Spirito Hospital, Rome, Italy.
  • Manfrini S; Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy.
  • Lauro D; Department of Internal Medicine, University "Tor Vergata", Rome, Italy.
  • Frontoni S; Department of Internal Medicine, University "Tor Vergata", Rome, Italy.
  • Pozzilli P; Department of Endocrinology and Diabetes, University Campus Bio Medico, Rome, Italy.
  • Buzzetti R; Centre of Diabetes, Bart's and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
J Diabetes ; 8(1): 41-4, 2016 Jan.
Article en En | MEDLINE | ID: mdl-26118939
ABSTRACT
This document has been developed by a group of Italian diabetologists with extensive experience in continuous subcutaneous insulin infusion (CSII) therapy to provide indications for the clinical management of CSII in diabetic patients (both type 1 and type 2) based on delivery mode operating in Italy. Although the potential benefits of pump therapy in achieving glycemic goals is now accepted, such results cannot be obtained without specific knowledge and skills being conveyed to patients during ad hoc educational training. To ensure that these new technologies reach their full effectiveness, as demonstrated theoretically and clinically, a careful assessment of the overall therapeutic and educational process is required, in both qualitative and quantitative terms. Therefore, to ensure the cost-effectiveness of insulin pump therapy and to justify reimbursement of therapy costs by the National Health System in Italy, in this article we present a model for diabetes and healthcare centers to follow that provides for different levels of expertise in the field of CSII therapy. This model will guarantee the provision of excellent care during insulin pump therapies, thus representing the basis for a successful outcome and expansion of this form of insulin treatment in patients with diabetes while also keeping costs under control.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Infusiones Subcutáneas / Hipoglucemiantes / Insulina Tipo de estudio: Guideline / Qualitative_research Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Diabetes Asunto de la revista: ENDOCRINOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Infusiones Subcutáneas / Hipoglucemiantes / Insulina Tipo de estudio: Guideline / Qualitative_research Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Diabetes Asunto de la revista: ENDOCRINOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Italia
...